Please assess the completion status of the following clinical trial:

Trial Title: Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female child outpatients aged 5 to 18 years~2. Diagnosis of PWS confirmed by genetic testing and patient medical records and history~3. Stable pharmacologic, educational, behavioral and/or dietary interventions for 4 weeks prior to the study start, and for the duration of the study.~4. Have a physical exam and laboratory results that are within the norms for PWS~5. Have a parent/caregiver/guardian that is able to consent for their participation and complete assessments regarding the child's development and behavior improvement throughout the study.~Exclusion Criteria:~1. Exposure to any investigational agent in the 30 days prior to randomization~2. Prior chronic treatment with oxytocin.~3. A primary psychiatric diagnosis other than ASD, including bipolar disorder, psychosis, schizophrenia, PTSD or major depressive disorder. These patients will be excluded due to potential confounding results.~4. Pregnant or lactating patients. IN-OXT has not been studied in pregnant or lactating women.~5. A medical condition that might interfere with the conduct of the study, confound interpretation of study results or endanger their own well-being.~6. Plan to initiate or change nonpharmacologic or pharmacologic interventions during the course of the study.~7. Females using an estrogen-based contraceptive. As an alternative to an estrogen based contraceptive, subjects will be counseled to use progesterone-based contraceptives; cervical caps; cervical sponges; or spermicidal foam in combination with a condom. Subjects will need to use a double barrier method to be in the study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal Oxytocin (Type: EXPERIMENTAL): Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
- Matched Placebo (Type: PLACEBO_COMPARATOR): Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).

Based on this trial design, predict the completion outcome and termination type (if applicable).